GSK says Ris—Rez Phase III ARTEMIS—008 showed efficacy in China
GSK highlighted Ris—Rez (an ADC) Phase III ARTEMIS—008 update from China, citing a 54% reduction in risk of death versus topotecan and longer median survival for ADC-treated patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.